AB042. Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in glioblastoma multiforme by reprogramming tumor microenvironment
Our results support that anti-VEGFR2 therapy can downregulate PAK4, reprogram the TME by increasing CD8+ T cells infiltration and activation, and enhance the therapeutic effect of anti-PD-L1 therapy on GBM cells.
Authors
- Youxin Zhou (ORCID: https://orcid.org/0000-0002-2835-8376)
- Yao Lin
- Hao Wang (ORCID: https://orcid.org/0000-0002-5723-0187)
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab042
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00